Spinal cord stimulator

Nalu Medical, Inc. Closes $85 Million Series E Round

Retrieved on: 
Tuesday, March 5, 2024

Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.

Key Points: 
  • Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.
  • Series E was led by Novo Holdings (Novo) with $65M of the total closing in late-December 2023.
  • Also participating in the round were all existing significant investors: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
  • “The Nalu Team is committed to addressing the unmet needs of patients suffering from chronic intractable neuropathic pain.

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the neuromodulation market across varied regions.

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • In 2022, internal neuromodulation dominated the global neuromodulation market.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.

Nalu Medical, Inc. Presents Long-term and Holistic Outcomes from the COMFORT RCT for PNS at NANS 2024

Retrieved on: 
Tuesday, January 23, 2024

The ongoing COMFORT RCT is a randomized, controlled, post-market, open-label, minimal risk, multi-center clinical study focused on evaluating the effectiveness of peripheral nerve stimulation (PNS) therapy with the Nalu Neurostimulation System to treat chronic pain in the shoulder, low back, knee, or ankle/foot.

Key Points: 
  • The ongoing COMFORT RCT is a randomized, controlled, post-market, open-label, minimal risk, multi-center clinical study focused on evaluating the effectiveness of peripheral nerve stimulation (PNS) therapy with the Nalu Neurostimulation System to treat chronic pain in the shoulder, low back, knee, or ankle/foot.
  • The study is designed to develop 3-year data to demonstrate the sustained pain relief and quality of life improvements achievable with the Nalu PNS system.
  • In the COMFORT RCT, we are measuring variables that present this broader picture.
  • “The COMFORT RCT is intended to provide reliable evidence of the sustained effectiveness and impact on quality of life provided by Nalu PNS therapy and to expand the use of Nalu PNS to patients for whom physicians have limited options.

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Retrieved on: 
Wednesday, January 17, 2024

REDWOOD CITY, Calif., Jan. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.

Key Points: 
  • Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.
  • A total of 25 scientific abstracts reviewing clinical results for 10 kHz Therapy™, including four podium presentations and 21 posters, will be presented at the conference.
  • "The growing body of clinical evidence from our 25 scientific abstracts displays the substantial benefits of 10 kHz Therapy and we look forward to continuing to treat underserved patient populations suffering from debilitating chronic pain."
  • The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

Saluda Medical Announces Late Breaking Data at NANS 2024 Annual Meeting

Retrieved on: 
Tuesday, January 16, 2024

MINNEAPOLIS, Jan. 16, 2024 /PRNewswire/ -- Saluda Medical, Inc., a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies, today announced the company's data will be presented at the North American Neuromodulation Society (NANS) 2024 Annual Meeting, taking place January 18-21.

Key Points: 
  • MINNEAPOLIS, Jan. 16, 2024 /PRNewswire/ -- Saluda Medical, Inc., a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies, today announced the company's data will be presented at the North American Neuromodulation Society (NANS) 2024 Annual Meeting, taking place January 18-21.
  • The 3-Year EVOKE Study demonstrated superior pain relief in the closed-loop (SmartLoop™) arm versus the open-loop arm.
  • The evidence presented at NANS demonstrates SmartLoop's capability to provide long-term superior outcomes for patients as well as advance SCS therapy efficiencies for clinical practices," said Jim Schuermann, President and CEO of Saluda Medical.
  • For more information, please visit us at NANS: Saluda Medical Booth #339.

Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain

Retrieved on: 
Wednesday, January 3, 2024

Nalu Medical Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing.

Key Points: 
  • Nalu Medical Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing.
  • The proceeds from this financing will be used to accelerate commercial growth, expand clinical and health-economic evidence, continue product development, and scale operations.
  • “We continue to invest in building clinical data to expand access for patients who often don’t have other therapeutic options.
  • Novo’s investment in Nalu reflects that progress and the confidence they share in the strong commercial potential for Nalu,” observed Geoff Pardo of Gilde Healthcare and Chairman of the Nalu Board.

Synchron Appoints Riki Banerjee as Chief Technology Officer

Retrieved on: 
Wednesday, January 3, 2024

Synchron , the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO).

Key Points: 
  • Synchron , the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO).
  • Banerjee will be responsible for leading all research and development (R&D) activities, including advancing Synchron’s neuroprosthesis device for patients with severe paralysis.
  • Banerjee will succeed Nick Opie, Ph.D., the founding CTO and co-founder of Synchron who remains on the Board of Directors.
  • Riki has led teams across engineering and scientific disciplines to translate medical technology to commercialized product.

Neurostimulation Technology and Global Markets Report 2023: 2020-2022 Data, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 20, 2023

This report provides a comprehensive study of the global market for neurostimulation technologies and devices.

Key Points: 
  • This report provides a comprehensive study of the global market for neurostimulation technologies and devices.
  • It provides a detailed description of the different types of neurostimulation technologies and devices (invasive and noninvasive) and their current and historical market revenues.
  • Currently, the potential of neurostimulation technology is actively being explored for other clinical conditions including obesity, tinnitus and central nerve system disorders.
  • An in-depth analysis of the global market for neurostimulation technologies and devices includes historical data and market projections by device type, therapeutic application and region.

Nalu Medical, Inc., Announces Positive Results of US Spinal Cord Stimulation Clinical Study in Pain Physician Journal

Retrieved on: 
Wednesday, November 29, 2023

Today the company announces publication of the SCS nPower™ US clinical study in the Pain Physician Journal that reports on clinical outcomes related to the use of the Nalu SCS System to treat patients suffering from chronic intractable pain of the of trunk and/or limbs, including unilateral or bilateral pain.

Key Points: 
  • Today the company announces publication of the SCS nPower™ US clinical study in the Pain Physician Journal that reports on clinical outcomes related to the use of the Nalu SCS System to treat patients suffering from chronic intractable pain of the of trunk and/or limbs, including unilateral or bilateral pain.
  • The SCS nPower US clinical study was a prospective, post-market observational study conducted at 15 comprehensive pain centers in the US.
  • The Nalu Neurostimulation System was evaluated in 35 subjects with chronic low back and leg pain from baseline to 3 months.
  • Highlights of the results include:
    The wearable Therapy Disc was reported by all patients to be comfortable and easy to use.